Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 81.86M | 55.25M | 682.00K | 0.00 | 0.00 | 0.00 |
Gross Profit | 70.59M | 47.28M | 515.00K | -620.00K | -521.00K | -300.00K |
EBITDA | -274.92M | -261.52M | -159.05M | -171.82M | -134.56M | -124.19M |
Net Income | -251.47M | -334.33M | -201.59M | -223.01M | -148.09M | -133.32M |
Balance Sheet | ||||||
Total Assets | 294.21M | 378.32M | 413.84M | 164.81M | 189.43M | 295.11M |
Cash, Cash Equivalents and Short-Term Investments | 212.31M | 297.26M | 381.39M | 155.38M | 183.26M | 287.50M |
Total Debt | 203.56M | 201.91M | 139.03M | 97.07M | 91.34M | 49.02M |
Total Liabilities | 632.58M | 631.90M | 486.60M | 239.62M | 117.28M | 100.84M |
Stockholders Equity | -338.38M | -253.58M | -72.76M | -74.81M | 72.16M | 194.27M |
Cash Flow | ||||||
Free Cash Flow | -282.66M | -266.90M | -139.21M | -147.57M | -148.94M | -70.73M |
Operating Cash Flow | -282.68M | -266.77M | -137.58M | -146.53M | -148.62M | -69.69M |
Investing Cash Flow | -113.00K | -135.00K | -1.63M | -1.04M | -328.00K | -1.04M |
Financing Cash Flow | 172.87M | 182.77M | 367.58M | 120.04M | 44.71M | 114.46M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
71 Outperform | $337.43M | 9.11 | 531.78% | ― | 68.74% | ― | |
61 Neutral | $248.59M | 8.10 | 7.22% | ― | 5.74% | 24.45% | |
54 Neutral | $684.60M | ― | -83.24% | ― | -100.32% | -197.69% | |
54 Neutral | $640.89M | ― | 181.41% | ― | 3055.71% | -18.80% | |
52 Neutral | $7.52B | 0.25 | -63.76% | 2.30% | 16.15% | 0.89% | |
47 Neutral | $335.48M | ― | -48.57% | ― | -100.00% | 83.98% | |
40 Underperform | $279.98M | ― | -59.60% | ― | -100.00% | 31.43% |
On June 16, 2025, Phathom Pharmaceuticals announced that the FDA updated the Orange Book to reflect a full 10-year period of non-patent New Chemical Entity exclusivity for VOQUEZNA tablets. This correction confirms VOQUEZNA’s exclusivity through May 3, 2032, supporting its long-term commercial potential and aligning with statutory requirements.
The most recent analyst rating on (PHAT) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Phathom Pharmaceuticals stock, see the PHAT Stock Forecast page.
On June 3, 2025, Phathom Pharmaceuticals held its Annual Meeting of Stockholders, where key decisions were made regarding the election of directors, ratification of the accounting firm, and executive compensation. The stockholders elected Class III directors, ratified Ernst & Young LLP as the accounting firm for 2025, approved executive compensation, and decided to hold annual votes on executive compensation, aligning with the board’s recommendations.
The most recent analyst rating on (PHAT) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Phathom Pharmaceuticals stock, see the PHAT Stock Forecast page.
On June 6, 2025, Phathom Pharmaceuticals announced that the FDA approved their Citizen Petition, filed in December 2024, to correct the Orange Book and recognize a 10-year New Chemical Entity exclusivity for VOQUEZNA® (vonoprazan) tablets, extending through May 3, 2032. This approval enhances Phathom’s market position by securing extended exclusivity for their product, potentially impacting their commercialization strategy and competitive landscape in the gastrointestinal treatment market.
The most recent analyst rating on (PHAT) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Phathom Pharmaceuticals stock, see the PHAT Stock Forecast page.
Phathom Pharmaceuticals has appointed Theodore R. Schroeder to its Board of Directors as a Class I director, effective April 16, 2025. Mr. Schroeder, with over 30 years of experience in drug development and commercialization, will serve on the audit committee and brings significant leadership experience from his previous roles at various pharmaceutical companies. His appointment is expected to strengthen the board with his extensive industry knowledge and leadership skills.